Crossmark

Patient and clinician experiences with the implementation of telemedicine and related adaptations in office-based buprenorphine treatment during the COVID-19 pandemic: a qualitative study

Crossref DOI link: https://doi.org/10.1186/s13722-025-00536-3

Published Online: 2025-03-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Davoust, Melissa

Bazzi, Angela R.

Blakemore, Samantha

Blodgett, Juliana

Cheng, Anna

Fielman, Sarah

Magane, Kara M.

Theisen, Jacqueline

Saitz, Richard

Ventura, Alicia S.

Weinstein, Zoe M.
Funding

Funding for this research was provided by:

National Institute on Drug Abuse (T32DA041898, K01DA043412)

National Center for Advancing Translational Sciences (1UL1TR001430, 1UL1TR001430, 1UL1TR001430, 1UL1TR001430)
License Information

Text and Data Mining valid from 2025-03-04

Version of Record valid from 2025-03-04
More Information

Article History

Received: 16 April 2024

Accepted: 7 January 2025

First Online: 4 March 2025

Declarations

:

: The Boston University Medical Campus Institutional Review Board approved all study protocols. Informed consent was obtained from all individual participants included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below